drugset
drugset / Trial / NCT04569227

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

NCT04569227 ↗

Phase 2 Unknown 60 enrolled Enzychem Lifesciences Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

Timeline

Start
2021-04-30
Primary completion
2021-09
Completion
2021-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MOSEDIPIMOD Small molecule 2000 mg Oral

Indications

pneumonia